Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial
Two Patients Treated with CRISPRed Cells in Immunotherapy Trial

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

cancer immunotherapy
Tuberculosis Can Emerge After Cancer Immunotherapy
Tuberculosis Can Emerge After Cancer Immunotherapy
Ashley Yeager | Apr 1, 2019
At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Kerry Grens | Apr 1, 2019
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Catherine Offord | Jan 15, 2019
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Fecal Transplant Heals Colitis Caused by Immunotherapy
Fecal Transplant Heals Colitis Caused by Immunotherapy
Anna Azvolinsky | Nov 12, 2018
A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.
Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
Cell and Gene Therapy Tracker: Global CAR T-Cell Trials
The Scientist Staff | Aug 22, 2018
Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.
Opinion: Learning from Immunotherapy’s Recent Failures
Opinion: Learning from Immunotherapy’s Recent Failures
Luis Felipe Campesato | Aug 1, 2018
The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.